New Drugs Target Recurrent Meningioma

Major Finding: Two phase II studies of vatalanib and sunitinib showed 6-month progression-free survival rates of 57% and 36%, respectively.

Data Source: Two cohorts of 25 and 36 patients with recurrent grade II and III meningiomas.

Disclosures: Pfizer funded the study on its drug, sunitinib, and Novartis funded the study on its investigational drug, vatalanib. The investigators reported that they did not have any relevant conflicts of interest.*